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Abstract
Using a carcinogen-initiated rat model of mammary tumorigenesis, we tested the hypothesis that
transforming growth factor (TGF)-bs are useful biomarkers of chemopreventive efficacy in the breast.
The chemopreventive agents tested were tamoxifen and the retinoids 9-cis-retinoic acid (9cRA) and
N-(4-hydroxyphenyl)retinamide (4-HPR), because both antiestrogens and retinoids have previously
been shown to upregulate TGF-bs in vitro. Despite demonstrable chemopreventive efficacy in this
model, none of these agents, alone or in combination, had any significant impact on the expression of
TGF-bs in the mammary ductal epithelium or periductal stroma as determined by
immunohistochemistry. These data suggest that TGF-bs are not likely to be useful biomarkers of
chemopreventive efficacy in a clinical setting.
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Synopsis
Introduction: Chemoprevention has been defined as the use of
noncytotoxic nutrients or pharmacologic agents to enhance
intrinsic physiologic mechanisms that protect the organism
against the development of mutant clones and their progression
to malignant cancer. In a recent landmark trial, tamoxifen, a
hormonally active selective estrogen receptor modulator (SERM),
was shown to decrease the risk of invasive breast cancer by 49%
in asymptomatic, but at-risk women [1]. The search is now on for
agents with improved risk–benefit profiles, and for agents that will
prevent the subclass of estrogen receptor-negative tumors, the
incidence of which was unaffected by the SERMS. Retinoids
have already shown potential in this regard [2–7]. Because it will
not be possible to test many agents in large randomized clinical
trials, efforts are underway to develop useful tissue-based
surrogate end-point biomarkers that can be used to select only
the most promising agents (and doses) for large-scale trials.
Provocative mechanistic connections have been made
between the steroid hormone superfamily, including the
SERMS and retinoids, and the TGF-b family of multifunctional
growth factors [8]. The TGF-b system has tumor suppressor
activity, and loss of TGF-b response is associated with
advanced disease in many human tumor types, including the
breast [9,10]. Conversely, experimental overexpression of
TGF-b in the mammary gland protects against tumorigenesis
[11]. This strongly suggests that interventions that enhance
TGF-b function early in tumorigenesis could delay or prevent
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the course of the disease. SERMs such as tamoxifen can
upregulate TGF-b production and activation by many cell
types, including human breast cancer cell lines [12–15].
Similarly, retinoids can upregulate TGF-b production and
activation, both in cell culture and in rats in vivo [16,17]. It is
plausible, therefore, that upregulation of endogenous TGF-b
could contribute to the chemopreventive efficacy of SERMs
and retinoids.
In the present study we used a carcinogen-induced rat
mammary carcinogenesis model to test the hypothesis that
chemoprevention by tamoxifen and retinoids is associated with
local upregulation of TGF-bs in the mammary gland, and that
TGF-bs might therefore be useful as potential surrogate end-
point biomarkers of chemopreventive efficacy in clinical trials.
Materials and methods: A standard protocol for induction of
breast cancer in female Sprague–Dawley rats using a single
dose of N-nitroso-N-methylurea (NMU) at 8 weeks of age was
used [4,18]. Chemopreventive agents were incorporated into
powdered lab chow [18] and fed ad libitum, beginning 1 week
after injection with NMU. The rats were fed 9cRA (Kuraray
Company, Osaka, Japan) at 120mg/kg of diet, tamoxifen (Sigma
Chemical Co, St Louis, MO, USA) at 1.0mg/kg of diet, and
4-HPR (RW Johnson Pharmaceutical Research Unit, Spring
House, PA, USA) at 782mg/kg of diet.
Rats were weighed and palpated for the presence of mammary
tumors weekly, and six rats in each experimental group were
sacrificed after 6 and 12 weeks of treatment with chemopreventive
agent. For experiments to determine the effect of high doses of
tamoxifen administered over shorter periods of time, rats were
given 10mg tamoxifen/kg body weight per day intragastrically, or
1mg tamoxifen/kg in the diet, and were sacrificed after 1 day or
3 weeks of treatment. All palpated tumors were confirmed at
necropsy, and mammary glands were fixed in neutral buffered
formalin and embedded in paraffin. The number 2 (first thoracic)
mammary gland was sectioned for histology and immuno-
histochemistry.
Immunohistochemical staining was done using rabbit
polyclonal antibodies raised against synthetic peptides that
correspond to regions in the mature forms of TGF-b1, TGF-b2
and TGF-b3: anti-TGF-b1-LC and anti-TGF-b1-CC [19], anti-
TGF-b2 (sc-90; Santa Cruz Biotechnologies Inc, Santa Cruz,
CA, USA), and anti-50-60-b3-LC [20], respectively. Anti-latent
TGF-b-binding protein (LTBP; Ab39) was raised against the
purified full-length platelet LTBP [21]. The antibodies were
affinity purified against the immunizing peptide (anti-TGF-b3) or
against protein A sepharose (anti-TGF-b1-LC, anti-TGF-b1-CC
and anti-TGF-b2). Immunohistochemical staining was
performed using an indirect immunoperoxidase detection
protocol (Vectastain Elite kit, Vector Laboratories, Burlingame,
CA, USA). Staining intensity was scored on a scale of 0–4+,
using the mouse embryo control section as a reference
standard for each run. Ducts and periductal stroma were
scored independently. Staining was scored in a blinded
manner by two independent observers, and discrepancies
were rescored by consensus. Staining intensity was plotted as
the mean±standard deviation for each experimental group.
Results: Palpable mammary tumors were first detected after
approximately 35 days following initiation of NMU, and by
70 days incidence had reached 100% in rats not treated with
chemopreventive agents (Fig. 1a). Tamoxifen, alone or in
combination with retinoids, decreased tumor incidence by
more than 70% by the end of the study, whereas 9cRA alone
decreased it by 50%. 4-HPR alone had a relatively modest
effect on tumor incidence in the present study. However, it
significantly decreased tumor multiplicity (Fig. 1b), indicating
that the dose used was efficacious. There was minimal toxicity
associated with the chemopreventive intervention, except in the
tamoxifen + 4-HPR group, in which mild toxicity was observed,
as judged by the weights of the experimental animals (Fig. 1c).
Figure 1
Effect of chemopreventive agents on mammary tumor formation in the
NMU rat model of mammary tumorigenesis. Rats were administered
NMU at 8 weeks of age (time t=0), and were randomized into six
groups which were given the following chemopreventive agents
continuously in their diet, starting 1 week after initiation: no additions
(s), 4-HPR (d), 9cRA (h), tamoxifen (j), 4-HPR + tamoxifen (n), or
9cRA + tamoxifen (m). Rats were weighed and palpated for tumors
each week. (a) Percentage of rats with palpable tumors. (b) Mean
number of tumors per rat. (c) Mean weight of rat. The open arrow
indicates the start of the chemopreventive intervention.All three TGF-b isoforms and the LTBP (part of the naturally
occurring latent TGF-b complex) showed broadly similar
immunostaining patterns in the mammary glands of untreated
rats at 15 weeks of age (Fig. 2). They were present both in the
ductal epithelium and in the periductal stroma, suggesting that
the TGF-bs are synthesized by the epithelial cells, and possibly
stromal cells, and are sequestered in the extracellular matrix.
This staining pattern is consistent with a role for the TGF-bs in
the maintenance of normal mammary homeostasis.
None of the chemopreventive agents used, alone or in
combination, were found to affect expression of any of the TGF-b
isoforms or the LTBP in either ductal epithelium or periductal
stroma after 6 weeks of chemopreventive intervention (Fig. 3). The
6-week time point was chosen as representative of the period of
preneoplasia, as the majority of the animals had no palpable
tumors at this time (Fig. 1). In the study set, eight out of 36 (22%)
of the slides showed histologic evidence of hyperplasia, one out
of 36 had a ductal carcinoma in situ (mammary intraepithelial
neoplasia [22]), and one out of 36 had a carcinoma. We further
investigated the effect of tamoxifen at higher doses and earlier
time points. In rats that received tamoxifen at 10mg/kg per day
intragastrically (equivalent to 600mg/day for a human) or 1mg/kg
per day intragastrically (equivalent to 60mg/day for a human) for
either 1 day or 3 weeks, again no consistent changes were seen
in TGF-b expression, using either the TGF-b1-CC or the TGF-b2
antibodies (data not shown).
After 6 weeks of treatment, we noticed that mammary glands
from tamoxifen-treated rats were less developed than those of
untreated control animals, having fewer tertiary ducts and
Breast Cancer Research    Vol 3 No 1 Zujewski et al
Figure 2
Immunohistochemical analysis of TGF-b expression in the rat mammary
gland. The first thoracic (number 2) mammary gland was harvested
from 15-week-old rats that had been treated with NMU at age
8 weeks. Sections were immunostained (see Materials and method),
with the following antisera: (a) anti-TGF-b1-LC (stains predominantly
intracellular TGF-b1); (b) anti-TGF-b1-CC (stains extracellular TGF-b1);
(c) anti-TGF-b2; (d) anti-TGF-b3; (e) anti-LTBP; and (f) normal rabbit
immunoglobulin. The brown stain indicates a positive
immunoperoxidase reaction. Images were shot at 630× original
magnification.
Figure 3
Lack of effect of chemopreventive agents on expression of TGF-bs in
the NMU-initiated rat mammary gland. Immunohistochemical staining
intensity for TGF-bs and LTBP was determined after 6 weeks of
treatment with the following chemopreventive agents: None (C);
4-HPR (H); 9cRA (R); tamoxifen (T); 4-HPR + tamoxifen (T/H); 9cRA +
tamoxifen (T/R). Staining intensity was determined independently for
the ductal epithelial cells and the periductal stroma (see Materials and
method). Staining intensity ranged from 0 to 4 (max). Results are given
as the mean ± SD for five or six rats/group. TGF-b1-LC is an antibody
that predominantly recognizes intracellular TGF-b1, whereas
TGF-b1-CC recognizes extracellular TGF-b1.Available online http://breast-cancer-research.com/content/3/1/066
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terminal end buds, and they could consistently be identified
from a blind data set (Fig. 4). By 12 weeks of treatment, all
three chemopreventive agents had a significant effect on
glandular histology, with tamoxifen and 9cRA showing the
greatest suppression of ductal development and lobule
formation, and 4-HPR showing a relatively mild effect.
Discussion: One major goal in the field of prevention is the
identification of surrogate biomarkers that might rapidly predict
the effect of a given agent on the primary end-point of cancer
incidence. The most informative markers are those with
modulation that is likely to be directly related to the preventive
effect, and a compelling argument can be made that TGF-bs
may fall into this category. However, the present data in a well-
established preclinical model of breast cancer, employing a
variety of highly effective chemopreventive regimens, suggest
that this is not the case.
Most of the previous studies on the regulation of TGF-bs by
tamoxifen and retinoids have been done in tissue culture
[12–14,17]. The lack of effect on TGF-b expression in the
present in vivo study may reflect the dependence of the
response on contextual cues that are only present in the
artificial  in vitro environment. In an in vivo study [16], all-trans-
retinoic acid was shown to cause an upregulation of TGF-b
isoforms in rats, with kinetics and isoform selectivity that
varied with the target tissue. However, the rats were vitamin
A-deficient, and it is not known whether the same effects
would be seen in vitamin A-replete animals such as were
used in the present study. In a small study in humans [23]
tamoxifen treatment was shown to cause a consistent
induction in extracellular TGF-b in breast cancer biopsies,
when compared with pretreatment biopsies from the same
patients, and complex effects of tamoxifen on induction of
TGF-b2 in the plasma of patients with metastatic breast
cancer have been described [24]. It is possible that tamoxifen
is only effective in inducing TGF-b in the context of a tumor,
and not in the normal or initiated tissue that was the subject
of the present study. However, an optimal surrogate end-
point biomarker in a prevention setting needs to be
modulated in normal or premalignant tissues. Although we
cannot eliminate the possibility of more subtle effects of
chemopreventive agents on TGF-b bioavailability or cellular
responsiveness, in our preliminary analyses we have seen no
effects on the expression of type I and type II TGF-b
receptors (data not shown).
There is considerable evidence to suggest that, at late stages
in tumorigenesis, TGF-bs can actually promote the tumorigenic
process, particularly if the epithelial cells have lost
responsiveness to the growth inhibitory effects of TGF-b by this
time [9]. While the present work was in progress, a study was
reported [25] that showed that loss of the type II TGF-b
receptor can already be seen in a significant fraction of
hyperplasias without atypia in the human breast. Furthermore,
loss of the receptor correlated with increased risk of
subsequent development of invasive breast cancer. Thus, loss
of TGF-b response may be a very early event in the
development of human breast cancer. Because locally elevated
TGF-b levels could select for TGF-b-resistant cells, and
because TGF-bs can have oncogenic effects on the stroma, it
may actually be important for the safety profile of
chemopreventive agents to demonstrate that they do not
increase TGF-b levels in the at-risk breast. In this regard, this
demonstration that the expression of TGF-bs in the preclinical
rat model is unaffected by tamoxifen, 9cRA, or 4-HPR may
actually have positive implications, because all three agents are
already in clinical use.
The NMU-induced rat model of mammary tumorigenesis is
widely used for chemoprevention studies, and yields rapid
development of hormonally responsive mammary tumors with
100% incidence [2,4,18]. To do this, the initiating agent is
given at 8 weeks of age and the chemopreventive agent is
started a week later, during the period of active development of
the mammary gland. We observed that the histology of the
tamoxifen-treated mammary glands differed significantly from
control glands when examined after 6 weeks of tamoxifen
Figure 4
Treatment with tamoxifen affects the histology of the rat mammary
gland. Representative hematoxylin and eosin stained sections of the first
thoracic gland of 15-week-old rats that had undergone the following
treatments: (a, b) No treatment; moderate numbers of mammary gland
lobules are present containing primary, secondary and tertiary ductules,
as well as developing alveoli. (c, d) Initiation with NMU at 8 weeks of
age; no significant histologic differences are noted in mammary gland
development from that in untreated control animals. (e, f) Initiation with
NMU at 8 weeks, followed by treatment with tamoxifen from 9 to 15
weeks of age; scant numbers of atrophic primary and secondary
mammary gland ductules are noted, with no alveolar bud development
evident. (a, c, e) Shot at 100×; and (b, d, f) shot at 400× original
magnification. Breast Cancer Research    Vol 3 No 1 Zujewski et al
Introduction
Chemoprevention has been defined as the use of noncyto-
toxic nutrients or pharmacologic agents to enhance intrin-
sic physiologic mechanisms that protect the organism
against the development of mutant clones and their pro-
gression to malignant cancer [27]. Members of the nuclear
receptor superfamily are considered to be particularly
promising targets for chemoprevention, because of their
pivotal role in the regulation of metabolic, developmental,
and differentiation pathways [28]. In a recent landmark trial
[1], tamoxifen, a hormonally active SERM, was shown to
decrease the risk of invasive breast cancer by 49% in
asymptomatic, but at-risk women. Another SERM, ralox-
ifene, also shows promise [29]. These studies validate the
concept of using pharmacologic agents for prevention of
human breast cancer in apparently healthy individuals.
The search is now on for agents with improved
risk–benefit profiles, and for agents that will prevent the
subclass of estrogen receptor-negative tumors, the inci-
dence of which was unaffected by the SERMS. Retinoids,
a family of compounds structurally related to vitamin A,
have already shown potential in this regard [2–7]. Since it
will not be possible to test many agents in large random-
ized clinical trials, efforts are underway to develop useful
tissue-based surrogate end-point biomarkers that can be
used to select only the most promising agents (and
doses) for large-scale trials.
Provocative mechanistic connections have been made
between the steroid hormone superfamily, including the
SERMS and retinoids, and the TGF-b family of multifunc-
tional growth factors. TGF-bs are potent inhibitors of the
growth of many epithelial cell types [8]. Recent work has
implicated the TGF-b system as an important tumor sup-
pressor pathway, and loss of TGF-b response is associ-
ated with advanced disease in many human tumor types,
including the breast [9,10,30,31]. In mouse models, over-
expression of TGF-b1 in the mammary gland protects
against tumorigenesis [11], whereas local inactivation of
the type II TGF-b receptor enhances tumorigenesis [32].
This strongly suggests that interventions that enhance
TGF-b function early in tumorigenesis could delay or
prevent the course of the disease.
Antiestrogens such as tamoxifen have been shown to
upregulate TGF-b production and activation by many cell
types, including human breast cancer cell lines [12–15].
Similarly, retinoids can upregulate TGF-b production and
activation, both in cell culture and in rats in vivo [16,17].
Therefore, it is reasonable to propose that some of the
chemopreventive efficacy of these agents against breast
cancer in vivo could be mediated via a local upregulation
of TGF-bs, with concomitant enhancement of tumor sup-
pressor activity.
In the present study, we used a carcinogen-induced rat
model of mammary carcinogenesis to test whether chemo-
prevention by tamoxifen and by two different retinoids
(4-HPR, also known as fenretinide; and 9-cRA) is associ-
ated with local upregulation of TGF-bs in the initiated
mammary gland. If this were the case, TGF-bs might be
useful as potential surrogate end-point biomarkers in clini-
cal trials. However, the results show that TGF-b levels, as
detected immunohistochemically, are not affected by
tamoxifen or retinoids in this preclinical model of early-
stage breast cancer.
Materials and methods
Mammary carcinogenesis studies
A standard protocol for induction of breast cancer in
female Sprague–Dawley rats was used [4,18], with initia-
tion induced by a single intravenous dose of NMU
(50mg/kg body weight) at 8 weeks of age. Retinoids and
treatment, showing fewer terminal end-buds and less tertiary
branching. Part of the chemopreventive efficacy of
antiestrogens and retinoids in this model may therefore be due
to a generalized decrease in ductal development. Since
chemopreventive agents are unlikely to be given to humans
during the pubertal period, this form of preclinical model may
not accurately reflect the degree of chemopreventive benefit
that could be achieved in humans. Although the accelerated
time course and high penetrance of disease reduces the costs
of this model, it may be advisable to confirm efficacy of
promising agents in a model that delays application of the
chemopreventive agent until the mammary gland is fully
developed.
In conclusion, we have shown that treatment of rats with
tamoxifen or retinoids results in effective chemoprevention of
mammary tumorigenesis, without any detectable effect on local
expression of TGF-bs. Although we cannot rule out more subtle
effects on TGF-b activity, such as the activation of latent forms,
the data suggest that TGF-bs are not involved in the underlying
molecular mechanism of chemoprevention induced by these
agents. This agrees with in vitro work [26] that showed that
blockade of TGF-b signaling did not abrogate the growth
inhibitory effect of tamoxifen on breast cancer cells. Given the
very limited breast tissue available in clinical trials, we do not
recommend testing for TGF-bs as a surrogate end-point
biomarkers at this time.
Full articletamoxifen were incorporated into powdered laboratory
chow as described previously [18] and fed ad libitum,
beginning 1 week after injection with NMU. Rats were fed
9cRA (Kuraray Company, Osaka, Japan) at 120mg/kg of
diet, tamoxifen (Sigma Chemical Co, St Louis, MO, USA)
at 1.0mg/kg of diet, and 4-HPR (RW Johnson Pharma-
ceutical Research Institute) at 782mg/Kg of diet.
Rats were weighed weekly and palpated for the presence
of mammary tumors. Six rats in each experimental group
were sacrificed after 6 and 12 weeks of treatment with
chemopreventive agent. The 6-week sacrifice time was
chosen for the immunohistochemical studies to represent
the period of premalignancy, because the incidence of
palpable tumors is less than 20% for all experimental
groups at that time. By 12 weeks all rats that have not
received a chemopreventive agent have tumors, so the
primary purpose of the 12-week sacrifice time was to
allow an accurate determination of chemopreventive effi-
cacy for the particular experiment.
For experiments to determine the effect of high doses of
tamoxifen administered over shorter periods of time, rats
were given 10mg tamoxifen/kg body weight per day intra-
gastrically or 1mg tamoxifen/kg in the diet, and were sacri-
ficed after 1 day or 3 weeks of treatment.
All palpated tumors were confirmed at necropsy, and
mammary glands were fixed in neutral buffered formalin
and embedded in paraffin. The number 2 (first thoracic)
mammary gland was sectioned for histology and immuno-
histochemistry.
Immunohistochemistry of TGF-b bs
Immunohistochemical staining was done using rabbit poly-
clonal antibodies raised against synthetic peptides that cor-
respond to regions in the mature forms of TGF-b1, TGF-b2,
and TGF-b3. Antibodies to TGF-b1 were raised against a
synthetic peptide corresponding to residues 1–30 of the
mature protein in either the Laboratory of Chemoprevention
(anti-TGF-b1-LC; NIH, Bethesda, MD, USA) or the Collagen
Corporation (anti-TGF-b1-CC; Palo Alto, CA, USA). These
antibodies were raised against different preparations of the
1–30 peptide, and they recognize different epitopes of this
peptide [19]. The LC antibody usually stains intracellular
TGF-b1, whereas the CC antibody stains extracellular
TGF-b1. Anti-TGF-b2 (sc-90; Santa Cruz Biotechnologies
Inc) was raised to a peptide corresponding to residues
72–99 of the mature TGF-b2. Anti-TGF-b3 (anti-
50-60-b3-LC) was raised against residues 50–60 of mature
TGF-b3 [20]. Anti-LTBP (Ab39) was raised against the puri-
fied full-length platelet LTBP [21].
The antibodies were affinity purified against the immuniz-
ing peptide (anti-TGF-b3) or against protein A sepharose
(anti-TGF-b1-LC, anti-TGF-b1-CC, and anti-TGF-b2), and
have been assayed for specificity by Western blot analy-
sis [19,20,33]. All antibodies reacted with the appropri-
ate TGF-b isoform except anti-TGF-b1-CC, which showed
some cross-reactivity with TGF-b3 on Western blots.
Immunohistochemical staining was performed using an
indirect immunoperoxidase detection protocol (Vectas-
tain Elite kit; Vector Laboratories) following treatment of
sections with hyaluronidase to improve antibody penetra-
tion. Optimal antibody concentrations were determined
by titration on select samples before analysis of the full
experimental set. Staining was shown to be specific in
control experiments in which either the primary antibody
was preincubated with a 50-fold molar excess of immu-
nizing peptide before being applied to the section (anti-
TGF-b2, anti-TGF-b3), or the section was stained with an
equivalent concentration of nonimmune rabbit immuno-
globulin (anti-TGF-b1-LC, anti-TGF-b1-CC, and anti-
LTBP). In analysis of the full experimental set, for any
given antibody all sections were stained at the same time
so as to be directly comparable, and a normal mouse
embryo section was included as a positive control. A
normal rabbit immunoglobulin control was also run for
the whole set.
Quantitation of immunostaining
Two different systems were used to grade immunostain-
ing. For all samples, staining of the ducts and periductal
stroma were scored independently. For samples after
6 weeks of chemopreventive treatment, staining intensity
was scored on a scale of 0–4+, using the mouse embryo
control section as a reference standard for each run.
Staining was scored in a blinded manner by two indepen-
dent observers, and scores never differed by more than
one point. Discrepancies were rescored by consensus.
Staining intensity was plotted as the mean±standard
deviation for each experimental group.
Results
Chemopreventive efficacy
Palpable mammary tumors were first detected after approx-
imately 35 days following initation with NMU, and by
70 days incidence had reached 100% in rats not treated
with chemopreventive agents (Fig. 1a). Tamoxifen, alone or
in combination with retinoids, decreased tumor incidence
by more than 70% by the end of the study, whereas 9cRA
alone decreased it by 50%. 4-HPR alone had a relatively
modest effect on tumor incidence in the present study.
However, it significantly decreased tumor multiplicity
(Fig. 1b) indicating that the dose used was efficacious.
These incidence and multiplicity data are consistent with
previously published studies using this model [2,4,34]. The
mean weights of the rats in the various experimental groups
differed by less than 10% from those of rats not treated
with a chemopreventive agent, except for the rats treated
with a combination of tamoxifen and 4-HPR, in which the
Available online http://breast-cancer-research.com/content/3/1/066
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untreated group by the end of the study (Fig. 1c). This sug-
gests that there was minimal toxicity associated with the
chemopreventive intervention, except in the tamoxifen +
4-HPR group, in which mild toxicity was observed.
Effect of chemopreventive agents on TGF-b b expression
in initiated mammary gland
Figure 2 shows the typical immunohistochemical staining
pattern for the TGF-bs and the LTBP (part of the naturally
occurring latent TGF-b complex) in initiated mammary
glands of 15-week-old rats that had not been treated with
chemopreventive agents. All three TGF-b isoforms and the
LTBP showed broadly similar staining patterns. They were
present both in the ductal epithelium and in the periductal
stroma, suggesting that the TGF-bs are synthesized by the
epithelial cells, and possibly stromal cells, and are
sequestered in the extracellular matrix. This staining
pattern is consistent with a role for the TGF-bs in the
maintenance of normal mammary homeostasis.
None of the chemopreventive agents used, alone or in
combination, were found to affect expression of any of the
TGF-b isoforms or the LTBP in either ductal epithelium or
periductal stroma after 6 weeks of chemopreventive inter-
vention (Fig. 3). The 6-week time point was chosen as rep-
resentative of the period of preneoplasia, because the
majority (>80%) of the rats had no palpable tumors at this
stage (Fig. 1). Human clinical material for biomarker analy-
sis in primary chemoprevention studies is also likely to
comprise normal and initiated, at-risk epithelium with some
early preneoplastic changes, but without evidence of
major neoplastic change.
In the 6-week study set, eight out of 36 (22%) of the
glands sampled showed histologic evidence of hyperpla-
sia. In addition, one out of 36 glands sampled had a
lesion with the appearance of a ductal carcinoma in situ
(focal necrosis, marked atypia and abundant mitoses,
placing it in the category of ‘mammary intraepithelial neo-
plasia’ by the Annapolis naming convention [22]), and an
additional one had an invasive carcinoma. Both the in situ
and the invasive carcinomas were in the control group.
However, both samples also had histologically normal
ducts on the same slide, which were scored for the analy-
sis. There was no difference in staining between the
ducts that were proximal to the tumor and those that were
more distal, and neither were there any differences in
staining observed between histologically normal and
hyperplastic ducts in any of the samples analyzed (data
not shown). Since the focus of the present study was on
TGF-b expression changes in the preneoplastic gland,
staining of the tumors was not scored for the analysis, but
in the two cases present, the staining did not differ signif-
icantly from that of the surrounding normal-appearing
ducts (not shown).
Assuming that a rat weighs approximately 250g and eats
10g of chow each day, the equivalent human doses to
those used in this study would be approximately
2.5mg/day tamoxifen, 2g/day 4-HPR, and 290mg/day
9cRA. The human doses that are currently being used in
clinical trials are 20mg/day for tamoxifen, 0.2–0.4g/day
for 4-HPR, and 100–250mg/day for 9cRA. The different
doses of tamoxifen and 4-HPR used in humans and rats
probably reflect interspecies differences in pharmacoki-
netics. However, because the efficacious dose for tamox-
ifen was 10 times lower in the rat than the dose that has
previously been shown to upregulate TGF-b1 expression
in human breast tumor tissue [23], we looked at the effect
of a higher dose of tamoxifen in the rats. Furthermore,
because one study [35] showed that TGF-b may be tran-
siently upregulated early after administration of tamoxifen,
we also looked at earlier time points. In rats receiving
tamoxifen at 10mg/kg per day intragastrically (equivalent
to 600mg/day for a human) or 1mg/kg per day (equiva-
lent to 60mg/day for a human) for either 1 day or 3 weeks,
again no consistent changes were seen in TGF-b expres-
sion, using either the TGF-b1-CC or the TGF-b2 antibodies
(data not shown).
Effect of chemopreventive agents on the histology of
the mammary gland
While scoring the immunohistochemical slides, we
noticed that the mammary histology appeared to be
altered in rats treated with chemopreventive agents.
Hematoxylin and eosin stained sections from the samples
after 6 weeks of treatment were analyzed by a veterinary
pathologist (MAE). The mammary glands from tamoxifen-
treated rats were less developed than those of untreated
control animals, having fewer tertiary ducts and terminal
end-buds, and could consistently be identified from a blind
data set (Fig. 4). By 12 weeks of treatment, all three
chemopreventive agents had a significant effect on glan-
dular histology, with tamoxifen and 9cRA showing the
greatest suppression of ductal development and lobule
formation, and 4-HPR showing a relatively mild effect.
Discussion
TGF-b bs as candidate biomarkers
One major goal in the field of prevention is the identifica-
tion of surrogate biomarkers that might rapidly predict the
effect of a given agent on the primary end-point of cancer
incidence. There is an extensive literature showing that
steroid hormone superfamily members, such as antiestro-
gens and retinoids, can upregulate TGF-b activity in a
variety of systems [12–17,23,24,35]. This suggested that
the chemopreventive action of these agents against breast
cancer could be mediated in part through enhancing the
tumor suppressor activity of the endogenous TGF-b
system, and thus that changes in TGF-b expression might
serve as useful surrogate end-point biomarkers of chemo-
preventive efficacy. However, here we used the NMU-
Breast Cancer Research    Vol 3 No 1 Zujewski et alinduced rat model of mammary carcinogenesis to show
that the chemopreventive effect of tamoxifen and two
retinoids is not associated with any consistent changes in
TGF-b levels, at least as determined immunohistochemi-
cally.
Comparison with earlier studies
Most of the previous studies on the regulation of TGF-bs
by tamoxifen and retinoids [12–14,17] have been done in
tissue culture. Thus, the lack of effect on TGF-b expres-
sion in the present in vivo study might reflect the depen-
dence of the response on contextual cues that are only
present in the artificial in vitro environment. In one previ-
ous in vivo study [16] all-trans-retinoic acid upregulated
TGF-b expression in rats, with kinetics and isoform selec-
tivity that varied with the target tissue. However, the rats
were vitamin A-deficient, and it is not known whether the
same effects would be seen in vitamin A-replete animals,
such as were used in the present study, or whether the
response would vary with the specific retinoid used.
There are some data that support an effect of tamoxifen on
upregulation of TGF-bs in vivo in humans. Three months of
tamoxifen treatment was shown to cause a consistent
induction in extracellular TGF-b in breast cancer biopsies,
when compared with pretreatment biopsies from the same
patients [23]. Furthermore, complex effects of tamoxifen on
induction of TGF-b2 in the plasma of patients with metasta-
tic breast cancer have been described [24]. It is possible
that tamoxifen is only effective in inducing TGF-b in the
context of a tumor, and not in normal or initiated tissue,
which was the subject of the present study. This issue
could be reassessed in preclinical models using the same
agents to treat established proliferative intraepithelial neo-
plasia. However, for ease of tissue acquisition, an optimal
surrogate end-point biomarker in a prevention setting
needs to be modulated in normal or premalignant tissues.
Alternative levels of regulation of the bioefficacy of
TGF-b bs
Interestingly, in cell culture, both tamoxifen and all-trans-
retinoic acid have been shown [12–14,17] to increase the
fraction of TGF-b in its biologically active, as opposed to
its latent form. The current method for discriminating
between active and latent TGF-b in tissue samples
requires the use of frozen sections and immunofluores-
cence techniques, which are not practical for routine clini-
cal use [36]. As simpler assays become available,
however, the issue of possible changes in TGF-b activa-
tion status should be readdressed. Retinoids can also
affect cellular responsiveness to TGF-bs at the level of
receptor expression and downstream events [37,38]. To
date, expression of TGF-b receptors and downstream sig-
naling components such as the Smads have not been
well-characterized in this rat model, but in our preliminary
analyses we saw no effect of retinoids on type I and type II
TGF-b receptor expression in the mammary gland (data
not shown). At this time, however, we certainly cannot rule
out the possibility that tamoxifen and retinoids may be
having subtle effects on the TGF-b system at levels other
than the regulation of TGF-b expression.
Lack of effect of chemopreventive agents on TGF-b b
expression may have positive implications
There is considerable evidence to suggest that, at late
stages in tumorigenesis, TGF-bs can actually promote the
tumorigenic process, particularly if the epithelial cells have
lost responsiveness to the growth regulatory effects of
TGF-b by this time [9,39–41]. Thus, advanced human
tumors show increased levels of TGF-b expression
[42–44], and TGF-bs are known to suppress the immuno-
surveillance system, to enhance angiogenesis, invasion
and metastasis, and to increase drug resistance [45–48].
In the colon, loss of the type II TGF-b receptor occurs at
the late adenoma to carcinoma transition [49], suggesting
that early premalignant lesions retain TGF-b responsive-
ness and would be amenable to interventions that
enhance TGF-b activity. However, while the present work
was in progress, a study was reported [25] showing that
loss of the type II TGF-b receptor can already be seen in a
significant fraction of hyperplasias without atypia in the
human breast. Furthermore, loss of the receptor correlated
with increased risk of subsequently developing invasive
breast cancer. Thus, unlike in the colon, loss of TGF-b
response may be a very early event in the development of
human breast cancer.
Since locally elevated TGF-b levels may select for TGF-b-
resistant cells, and because TGF-bs can have oncogenic
effects on the stroma, it may actually be important for the
safety profile of chemopreventive agents to demonstrate
that they do not increase TGF-b levels in the at-risk
breast. For example, tamoxifen resistance in a xenograft
model of advanced human breast cancer was recently
shown [50] to be associated with an increase in TGF-bs
and concomitant immunosuppressive effects on natural
killer cells. In this regard, our demonstration that the
expression of TGF-bs in the preclinical rat model is unaf-
fected by tamoxifen, 9cRA, and 4-HPR may actually have
positive implications, because these agents are already in
clinical use.
Limitations of the NMU-induced rat model of mammary
carcinogenesis
The NMU-induced rat model of mammary tumorigenesis is
widely used for chemoprevention studies and yields rapid
development of hormonally responsive mammary tumors
with 100% incidence [2,4,18]. To do this, the initiating
agent is given at 8 weeks of age, during early puberty, and
the chemopreventive agent is typically given continuously,
starting 1 week later. Since sexual maturity is achieved at
Available online http://breast-cancer-research.com/content/3/1/066
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approximately 11 weeks of age in rats, this means that the
chemopreventive agent is given during a period of active
development of the mammary gland.
In the present study we observed that the histology of the
tamoxifen-treated mammary gland differed significantly
from control glands when examined after 6 weeks of
tamoxifen treatment. Specifically, there were fewer termi-
nal end-buds and less tertiary branching, which are indica-
tive of a delay or arrest in normal mammary development.
This is consistent with the known requirement for estrogen
for proper mammary development [51]. We saw a lesser
effect with 4-HPR, although this type of phenomenon has
also been described in the literature for retinoids [4]. Thus,
part of the chemopreventive efficacy of antiestrogens and
retinoids in this model may be due to a generalized
decrease in ductal development. Because chemopreven-
tive agents are unlikely to be given to humans during the
pubertal period, this form of preclinical model may not
accurately reflect the degree of chemopreventive benefit
that could be achieved in humans. Although the acceler-
ated time course and high penetrance of disease reduces
the costs of this model, it may be advisable to confirm effi-
cacy of promising agents in a model that delays applica-
tion of the chemopreventive agent until the mammary
gland is fully developed.
Conclusion
We have shown that treatment of rats with tamoxifen or
retinoids results in effective chemoprevention of mammary
tumorigenesis, without any detectable effect on local
expression of TGF-bs. Although we cannot rule out more
subtle effects on TGF-b activity, such as the activation of
latent forms, the data suggest that the underlying molecu-
lar mechanism of chemoprevention by these agents does
not involve increases in TGF-b expression. This agrees
with in vitro work showing that blockade of TGF-b sig-
nalling did not abrogate the growth inhibitory effect of
tamoxifen on breast cancer cells [26]. Given the very
limited breast tissue available in clinical chemoprevention
trials, we do not recommend testing for TGF-bs as surro-
gate end-point biomarkers at this time.
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